Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01455064 · ClinicalTrials.gov registry record

Navigator II Continuous Glucose Monitor Home Use Study

A clinical trial of Diabetes, sponsored by Abbott Diabetes Care.

Completed
Registry status
31
Enrollment target
2
Study locations

NCT01455064: Completed study of Diabetes, sponsored by Abbott Diabetes Care.

NCT01455064 is a study of Diabetes that has completed, run by Abbott Diabetes Care. The registered enrollment target is 31 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01455064, a study of Diabetes, has completed, sponsored by Abbott Diabetes Care.

COMPLETED
Registry status
31 participants
Enrollment target
2
Study locations

Study Summary

This research study will test a new investigational continuous glucose monitoring system (System). The purpose of this study is to find out about the performance of the System in a home use environment over a 15 day period, in people with diabetes.

Primary Outcome

Percentage of CGM results in the clinically accurate Zone A and percentage of CGM results in the clinically acceptable Zones A and B of the Clarke Error Grid versus blood glucose reference.

Conditions Studied

Interventions

  • DEVICE FreeStyle Navigator II Continuous Glucose Monitoring System

Study Locations (2)

Georgia

  • Atlanta Diabetes Associates - Atlanta

New Mexico

  • Southwest Clinical Research Center - Santa Fe

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2011-10
Est. Completion 2012-01
Abbott Diabetes Care

26 total trials

What the finished NCT01455064 record still lists

NCT01455064 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which FreeStyle Navigator II Continuous Glucose Monitoring System is the first listed.

NCT01455064 reports a single indexed study location in Georgia, New Mexico.

Frequently Asked Questions

What is clinical trial NCT01455064 about?

NCT01455064 is a clinical study titled "Navigator II Continuous Glucose Monitor Home Use Study". This research study will test a new investigational continuous glucose monitoring system (System). The purpose of this study is to find out about the performance of the System in a home use environment over a 15 day period, in people with diabetes.

What is the current status of trial NCT01455064?

This trial is currently completed. The enrollment target is 31 participants. The study started on 2011-10. Estimated completion is 2012-01.

What conditions does trial NCT01455064 study?

This clinical trial studies the following conditions: Diabetes.

What interventions are being tested in trial NCT01455064?

The interventions under investigation include: FreeStyle Navigator II Continuous Glucose Monitoring System (DEVICE).

Who is sponsoring clinical trial NCT01455064?

This trial is sponsored by Abbott Diabetes Care, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01455064 being conducted?

This trial has 2 study locations across Georgia, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01455064's enrollment target sits among peer trials

31 280th of 338 higher than 59 of 338 other Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01455064, the US trial registry maintained by the National Library of Medicine. NCT01455064 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.